Search Results - "Henry, Jason Timothy"

Current and evolving biomarkers for precision oncology in the management of metastatic colorectal cancer by Henry, Jason Timothy, Johnson, Benny

“…Colorectal cancer remains one of the most common cancers worldwide and is almost uniformly fatal for those with metastatic disease. Despite this, there is an…”
Get full text

Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001) by Henry, Jason Timothy, Mehnert, Janice M., Rudnicki, Erika, Pinelli, Juan, Daud, Adil

“…TPS9597 Background: SGN-BB228 is an investigational costimulatory Antibody Anticalin bispecific (Mabcalin) molecule directed to CD228 and 4-1BB. CD228 is a…”
Get full text

A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer by Johnson, Melissa Lynne, Henry, Jason Timothy, Spira, Alexander I., Battiste, James, Alnahhas, Iyad, Ahluwalia, Manmeet Singh, Barve, Minal A., Edenfield, William Jeffery, Nam, Do-Hyun, Eathiraj, Sudharshan, Hajdenberg, Julio, Yurasov, Sergey, Yu, Helena Alexandra, Wen, Patrick Y.

“…TPS9156 Background: The epidermal growth factor receptor (EGFR) is a potent oncogene commonly altered in many cancers, including glioblastoma (GBM) and…”
Get full text

First-in-human global multi-center study of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer by Perez, Cesar Augusto, Henry, Jason Timothy, Varkaris, Andreas, Subbiah, Vivek, Spira, Alexander I., Schmidt, Oleg, Shen, Jinshan, Guo, Wei, Hunter, Tamieka, Jen, Kai Yu, Padval, Mahesh, Karanovic, Djuro, Wolf, Beni B., Hamilton, Erika P.

“…TPS1124 Background: Targeting constitutively active mutant kinases with selective small molecule inhibitors is a key therapeutic pillar of precision oncology…”
Get full text

Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors by Diamond, Jennifer Robinson, Henry, Jason Timothy, Falchook, Gerald Steven, Olszanski, Anthony J., Singh, Harshabad, Leonard, E. Jane, Gregory, Richard C., Appleman, Vicky A., Gibbs, John, Harbison, Carole, Li, Cong, Sapiro, Jessica M., Yoneyama, Tomoki, Parent, Alexander A, Chung, Vincent

“…TPS2690 Background: Tumor resistance to immune checkpoint inhibitors (CPIs), including pembrolizumab, is common. Suggested mechanisms of resistance include…”
Get full text

First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors by Falchook, Gerald Steven, Liang, Yan, Harvey, R. Donald, Fu, Siqing, Weitao, Yao, Qin, Yan-ru, Zhang, Xiaojing, Henry, Jason Timothy, Zou, Qingping, Shan, Boyao, Liang, Pan, Wang, Chen, Li, Wenjia, Pamuklar, Zehra Nurgul, Pei, Yi, Chang, Zhiwei, Wang, Jiaqiang, Piha-Paul, Sarina A., Bhave, Manali A., Yin, Yongmei

“…3100 Background: Colony-stimulating factor 1 (CSF-1) pathway is involved in the development of various types of cancer. Pimicotinib is an orally available,…”
Get full text

Clinical and molecular presentation of KRAS G12D-mutated pancreatic ductal adenocarcinoma in real-world settings by Sturgill, Emma G., Kolli, Sahiti, Feustel, Kavanya, Luckett, Daniel, Jones, Carissa, Holt, Marilyn Elaine, Hyde, Annastasia, Jones, Suzanne Fields, Perez, Cesar Augusto, Wang, Judy S., Divers, Stephen G., Pelster, Meredith, Henry, Jason Timothy, Spigel, David R., Burris III, Howard A., McKenzie, Andrew Jacob

“…738 Background: Pancreatic ductal adenocarcinoma (PDAC) remains a devastating diagnosis with an overall 5-year survival rate of ~10%. Therapies targeting KRAS…”
Get full text